Viva Biotech Holdings (HKG:1873)
2.310
-0.050 (-2.12%)
Feb 13, 2026, 4:08 PM HKT
Viva Biotech Holdings Revenue
Viva Biotech Holdings had revenue of 831.87M CNY in the half year ending June 30, 2025, a decrease of -27.17%. This brings the company's revenue in the last twelve months to 1.84B, down -7.94% year-over-year. In the year 2024, Viva Biotech Holdings had annual revenue of 1.99B, down -7.84%.
Revenue (ttm)
1.84B CNY
Revenue Growth
-7.94%
P/S Ratio
2.42
Revenue / Employee
880.91K CNY
Employees
2,085
Market Cap
4.87B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.99B | -168.93M | -7.84% |
| Dec 31, 2023 | 2.16B | -224.05M | -9.42% |
| Dec 31, 2022 | 2.38B | 275.55M | 13.10% |
| Dec 31, 2021 | 2.10B | 1.41B | 201.90% |
| Dec 31, 2020 | 696.96M | 373.90M | 115.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AIM Vaccine | 1.38B |
| BioDlink International Company | 1.17B |
| Shandong Boan Biotechnology | 829.27M |
| Ocumension Therapeutics | 595.79M |
| Medtide | 546.29M |
| Qyuns Therapeutics | 351.04M |
| Jacobio Pharmaceuticals Group | 220.66M |
| Mirxes Holding Company | 166.32M |
Viva Biotech Holdings News
- 6 weeks ago - Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities - PRNewsWire
- 2 months ago - Sobi To Acquire Arthrosi Therapeutics - Nasdaq
- 2 months ago - Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. - PRNewsWire
- 4 months ago - Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry - PRNewsWire
- 5 months ago - Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights - PRNewsWire
- 6 months ago - Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth - PRNewsWire
- 11 months ago - Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection - PRNewsWire
- 11 months ago - Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D - PRNewsWire